期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

耐药结核病发病机制的研究进展 被引量：9

原文传递
导出
摘要 结核病是由MTB引起的传染性疾病,是全球仅次于艾滋病的第二大致死性感染性疾病.20世纪40年代以来随着抗结核药物的有效使用,结核病的发病率和死亡率曾一度大幅下降,但近年来由于耐药MTB的出现和广泛流行,结核病死灰复燃,给结核病的防控工作带来了严峻挑战.据世界卫生组织（WHO）估计,2013年全球报道的耐多药结核病（multidrug-resistant tuberculosis,MDR-TB）约30万例,其中9.0％的病例为广泛耐药结核病（extensively drug-resistant tuberculosis,XDR-TB）,而全球MDR-TB的治愈率仅为48％[1].因此,耐药结核病,尤其是MDR-TB已成为目前结核病防控工作的重点和难点.
作者 李勤静 焦伟伟 申阿东
机构地区 首都医科大学附属北京儿童医院、北京市儿科研究所儿科学国家重点学科教育部儿科重大疾病研究重点实验室儿童呼吸道感染性疾病研究北京市重点实验室
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2015年第9期691-694,共4页 Chinese Journal of Tuberculosis and Respiratory Diseases
基金 国家自然科学基金（81271889）
关键词 耐药结核病 TUBERCULOSIS 发病机制 MDR-TB 性感染性疾病 世界卫生组织 耐多药结核病 传染性疾病
分类号 R52 [医药卫生—内科学]
  • 相关文献

参考文献36

  • 1World Heath Organization.Global TB Report 2014[M].Gavena: World Health Organization,2014.
  • 2Zhao Y,Xu S,Wang L,et al.National survey of drug-resistant tuberculosis in China[J].N Engl J Med,2012,366(23):2161-2170.
  • 3Mehra M,Cossrow N,Kambili C,et al.Assessment of tuberculosis burden in China using a dynamic disease simulation model[J].Int J Tuberc Lung Dis,2013,17(9):1186-1194.
  • 4Seifert M,Catanzaro D,Catanzaro A,et al.Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review[J].PLoS One,2015,10(3):el 19628.
  • 5Almeida DS,Palomino JC.Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis:classical and new drugs[J].J Antimicrob Chemother,2011,66(7):1417-1430.
  • 6Machado D,Perdigao J,Ramos J,et al.High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations[J].J Antimicrob Chemother,2013,68(8):1728-1732.
  • 7宋艳华,高孟秋.结核分枝杆菌耐氨基糖苷类和多肽类抗结核药物分子机制的研究进展[J].中华结核和呼吸杂志,2012,35(7):531-533. 被引量：7
  • 8Maruri F,Sterling TR,Kaiga AW,et al.A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system[J].J Antimicrob Chemother,2012,67(4):819-831.
  • 9Blower SM,Chou T.Modeling the emergence of the ' hot zones': tuberculosis and the amplification dynamics of drug resistance[J]. Nat Med,2004,10(10):1111-1116.
  • 10Cohen T,Murray M.Modeling epidemics of multidrug-resistant M.tuberculosis of heterogeneous fitness[J].Nat Med,2004,10(10):1117-1121.

二级参考文献19

  • 1石瑞如,张健源,刘新,张国龙,李传友.链霉素耐药结核分枝杆菌临床分离株gidB基因突变研究[J].中国防痨杂志,2008,30(3):197-199. 被引量：5
  • 2[1]Zhao X,Drlica K.Restricting the selection of antibiotic-resistant mutants:a general strategy derived from fluoroquinolones studies[J].Clin Infect Dis,2001,33(Suppl):S147-S156.
  • 3[2]Drlica K.A strategy for fighting antibiotic resistance[J].ASM news,2001,67(1):27-33.
  • 4[3]Ddiea K.The mutant selection concentration and antimicrebial resistance[J].J Antimicrob Chemother,2003,52(1):11-17.
  • 5[4]Dong Y,Zhan X,Donmgal AJ,et al.Effect of fluoroquinolone concentration on selection of resistant mutants of mycobacteriumbovis BCG and staphylococcus aureus[J].Antimicrob Agents Chemother,1999,43(7):1756-1758.
  • 6[5]Blondeau JM,Zhao X,Hansen J,et al.Mutant prevention concentration of fluoroquinolones for clinical isolates of streptococcus pneumoniae[J].Antimicrob Agents Chemother,2001,45(2):433-438.
  • 7[6]Hansen G,Metzler K,Drlica K,et al.Mutant prevention concentration for gemifloxacin with clinical isolates of streptococcus pneumoniae[J].Antimicro Agents Chemother,2003,47(1):440-441.
  • 8[7]Firsov AA,Vostrov SN,Lubenkob IY,et al.In vitro pharmacedynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against staphylococcus aureus[J].Antimicrob Agents Chemother,2003,47(5):1604-1613.
  • 9[8]Zinner SH,Lubenko IY,Gilbea D,et al.Emergence of resistant streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window:related changes in susceptibility,resistance frequency and bacterial killin[J].J Antimicrob Chemother,2003,52(4):616-622.
  • 10[9]Firsov AA,Vostrov SN,Lubenko IY,et al.Prevention of the selection of resistant staphylococcus aureus by moxifloxacin plus doxyeycline in an in vitro dynamic model:an additive effect of the combination[J].Int J Antimicrob Agents,2004,23(5):451-456.

共引文献13

同被引文献62

引证文献9

二级引证文献118

中华结核和呼吸杂志
2015年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部